

A&I

ANÄSTHESIOLOGIE & INTENSIVMEDIZIN

Offizielles Organ: Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI)
Berufsverband Deutscher Anästhesisten e.V. (BDA)
Deutsche Akademie für Anästhesiologische Fortbildung e.V. (DAAF)
Organ: Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e.V. (DIVI)



Andersen diseases

Collagen VI-related myopathy

orphan**anesthesia**

a project of the German Society
of Anaesthesiology and Intensive Care Medicine

SUPPLEMENT NR. 2 | 2020

OrphanAnesthesia –

ein krankheitsübergreifendes Projekt des Wissenschaftlichen Arbeitskreises Kinderanästhesie der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e.V.

Ziel des Projektes ist die Veröffentlichung von Handlungsempfehlungen zur anästhesiologischen Betreuung von Patienten mit seltenen Erkrankungen. Damit will OrphanAnesthesia einen wichtigen Beitrag zur Erhöhung der Patientensicherheit leisten.

Patienten mit seltenen Erkrankungen benötigen für verschiedene diagnostische oder therapeutische Prozeduren eine anästhesiologische Betreuung, die mit einem erhöhten Risiko für anästhesieassoziierte Komplikationen einhergehen. Weil diese Erkrankungen selten auftreten, können Anästhesisten damit keine Erfahrungen gesammelt haben, so dass für die Planung der Narkose die Einholung weiterer Information unerlässlich ist. Durch vorhandene spezifische Informationen kann die Inzidenz von mit der Narkose assoziierten Komplikationen gesenkt werden. Zur Verfügung stehendes Wissen schafft Sicherheit im Prozess der Patientenversorgung.

Die Handlungsempfehlungen von OrphanAnesthesia sind standardisiert und durchlaufen nach ihrer Erstellung einen Peer-Review-Prozess, an dem ein Anästhesist sowie ein weiterer Krankheitsexperte (z.B. Pädiater oder Neurologe) beteiligt sind. Das Projekt ist international ausgerichtet, so dass die Handlungsempfehlungen grundsätzlich in englischer Sprache veröffentlicht werden.

Ab Heft 5/2014 werden im monatlichen Rhythmus je zwei Handlungsempfehlungen als Supplement der A&I unter www.ai-online.info veröffentlicht. Als Bestandteil der A&I sind die Handlungsempfehlungen damit auch zitierfähig. Sonderdrucke können gegen Entgelt bestellt werden.

OrphanAnesthesia –

a common project of the Scientific Working Group of Paediatric Anaesthesia of the German Society of Anaesthesiology and Intensive Care Medicine

The target of OrphanAnesthesia is the publication of anaesthesia recommendations for patients suffering from rare diseases in order to improve patients' safety. When it comes to the management of patients with rare diseases, there are only sparse evidence-based facts and even far less knowledge in the anaesthetic outcome. OrphanAnesthesia would like to merge this knowledge based on scientific publications and proven experience of specialists making it available for physicians worldwide and free of charge.

All OrphanAnesthesia recommendations are standardized and need to pass a peer review process. They are being reviewed by at least one anaesthesiologist and another disease expert (e.g. paediatrician or neurologist) involved in the treatment of this group of patients.

The project OrphanAnesthesia is international. Thus, all recommendations are published in English.

Starting with issue 5/2014, we'll publish the OrphanAnesthesia recommendations as a monthly supplement of A&I (Anästhesiologie & Intensivmedizin). They can be accessed and downloaded via www.ai-online.info. As being part of the journal, the recommendations will be quotable. Reprints can be ordered for payment.

Bisher in A&I publizierte Handlungsempfehlungen finden Sie unter:

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

A survey of until now in A&I published recommendations can be found on:

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

Projektleitung

Prof. Dr. Tino Münster, MHBA

Chefarzt
Klinik für Anästhesie und
operative Intensivmedizin
Krankenhaus Barmherzige
Brüder Regensburg
Prüfeninger Straße 86
93049 Regensburg,
Deutschland

Tel.: 0941 369-2350

E-Mail: Tino.Muenster@barmherzige-regensburg.de

orphananesthesia

Anaesthesia recommendations for Andersen disease

Disease name: Andersen disease (GSD IV)

ICD 10: E74.09

Synonyms: Adult polyglucosan body disease, amylopectinosis, Andersen disease, Andersen glycogenosis, brancher deficiency, branching enzyme deficiency, glycogen branching enzyme deficiency, glycogenosis type IV, glycogen storage disease IV, glycogen storage disease type 4, glycogenosis 4, glycogenosis type IV, GSD IV, GSD type IV, GSD4, type IV glycogenosis.

Disease summary: Andersen disease (GSD IV) is a rare genetic disorder of glycogen metabolism. It is caused by the deficient activity of the glycogen-branching enzyme, resulting in the accumulation of abnormal glycogen in the liver, muscles, and/or other tissues. The disease is inherited as an autosomal recessive trait. Clinically, the symptoms and findings become evident in the first months of life. Such features typically include failure to thrive and hepatosplenomegaly. In such cases, the course of the disease is typically characterised by progressive cirrhosis and liver failure, leading to potentially life-threatening complications. In addition, several neuromuscular variants of GSD IV have been described that may be evident at birth, in late childhood or in adulthood.

GSD IV was named after the principal investigator Dorothy Andersen who first described the disease in 1956.

GSD IV is a disorder of glycogen metabolism. Glycogen is a complex carbohydrate stored in cells of the body which is converted into glucose for use as energy. GSD IV is characterised by the deficient activity of the glycogen-branching enzyme (GBE1) which normally increases the number of branch points during the formation of glycogen. In most cases, deficient GBE1 activity leads to a generalised accumulation of the structurally abnormal glycogen. GBE1 is located at chromosome 3p14 and encodes for a 702 amino-acid protein [1–2]. Various specific mutations of the GBE gene have been identified including the classic hepatic form, those with non-progressive liver disease, and new-borns with the severe neuromuscular form. GSD IV accounts for 3/1000 of all glycogen storage diseases and 1 in 760'000 live births. GSD IV is inherited as an autosomal recessive trait. All individuals carry 4–5 abnormal genes [3–4].

GSD IV may vary in age at onset, symptoms and signs, degree of abnormal glycogen accumulation and specific organs affected. The most common, classic form of the disease is typically characterised by progressive cirrhosis to liver failure. In such cases, the disease typically becomes evident during infancy or up to about 18 months of age. Symptoms and signs commonly include failure to thrive and hepatosplenomegaly. In the majority of individuals with classic GSD IV, progressive liver disease may lead to liver transplantation or potentially life-threatening complications by roughly five years of age. However, there are rare cases reports of individuals having a non-progressive liver disease [5–7].

► **Citation:** Johnson M, Stuart G: Andersen disease. AnästH Intensivmed 2020;61:S13–19.
DOI: 10.19224/ai2020.S13

Several neuromuscular variants of GSD IV have also been described in the medical literature. There may be isolated muscle involvement beginning in late childhood, with myopathy and/or cardiomyopathy. Accumulation of the abnormal glycogen in a skeletal muscle may lead to muscle weakness and reduced exercise tolerance, and muscular atrophy. Those with cardiac involvement develop a dilated cardiomyopathy; symptoms may include fatigue, feeding difficulties, failure to thrive; shortness of breath with exertion and eventually at rest [2].

A fatal perinatal neuromuscular variant has been reported. This form may be characterised by hydrops, hypotonia, muscle atrophy and contractures, with neurologic involvement, leading to death usually in the neonatal period [9–11].

In addition, a rare neuromuscular variant has also been described in adults. This form of the disease, so-called adult polyglucosan body disease, may be characterised by dysfunction of the central and peripheral nervous systems. Individuals develop progressive muscle weakness, gait disturbances, mild cognitive impairment or dementia. [12]

GSD IV is usually diagnosed during infancy or childhood or, in some rare cases, in adulthood. Biopsy may demonstrate an abnormal deposition of amylopectin-like materials. However, testing to confirm the diagnosis requires detection of deficient GBE activity by an indirect enzyme assay [13–14].

The treatment of GSD IV is directed toward the specific symptoms that are apparent in each individual. Specific therapies are symptomatic and supportive and may include long-term management of cirrhosis and impaired liver function; neuromuscular disease; and/or cardiac failure. In individuals with progressive liver failure, liver transplantation has been conducted and may be effective in some cases. According to reports in the medical literature, following transplantation, some patients may develop progressive accumulation of abnormal glycogen in other organs, such as the heart, leading to potentially life-threatening complications. However, reports indicate that most patients have not had neuromuscular or heart complications, over follow-up periods of up to 13 years. In some of these patients, accumulations of glycogen in the heart and skeletal muscles have appeared to diminish following transplantation [7–8].

Genetic counselling will be of benefit for affected individuals and family members. Other treatment for this disorder is symptomatic and supportive.

Medicine is in progress



Perhaps new knowledge

Every patient is unique

Perhaps the diagnosis is wrong



Find more information on the disease, its centres of reference and patient organisations on Orphanet: www.orpha.net

Typical surgery

There are a number of published case series of paediatric liver transplantations performed for GSD IV between 1984 and 1999 with variable success. Liver transplantation for GSD IV is recognised but consideration needs to be taken of the extra-hepatic symptoms and the burden of disease [5–7] No comment is made in the papers to either anaesthetic or intensive care management.

Type of anaesthesia

Anaesthesia for individuals with GSD IV should be undertaken with care and precaution. Anaesthesia should ideally be undertaken in a specialist institution that has experience in the management of these children and adequate intensive care backup.

In principle, all types of anaesthesia can be used (i.e. regional and general as well as a combination of both).

Necessary additional pre-operative testing (beside standard care)

Routine bloods such as a full blood count, coagulation studies, blood chemistry including liver function and blood crossmatch should be taken when indicated and according to the standard requirements of the surgical procedure.

Diagnostic investigation and evaluation typically includes various studies to help detect and characterise certain abnormalities associated with GSD IV and include: laboratory studies, specialised imaging, e.g. abdominal ultrasound (USS), CT and MRI scanning, electromyography studies and echocardiography to assess cardiac structure and function.

Particular preparation for airway management

A difficult airway is not a classic feature of GSD IV.

Particular preparation for transfusion or administration of blood products

The classic form of the disease is typically characterised by progressive cirrhosis to liver failure with disease typically evident in early infancy up to about 18 months of age. They are therefore at risk of bleeding due to impaired liver function [5–7]. Careful pre-operative evaluation should be performed and planning undertaken into the preparation for transfusion and administration of blood products and consent taken from families. Discussion with haematology should be undertaken where indicated for support and advice.

Particular preparation for anticoagulation

Standard management.

Particular precautions for positioning, transportation and mobilisation

Standard management.

Interactions of chronic disease and anaesthesia medications

Standard management.

Anaesthetic procedure

There are no specific anaesthetic case reports or anaesthetic reviews of children with GSD IV. The only case report is mistitled GSD IV but is with regard to GSD IX [15].

Children with GSD IV should be anaesthetised after a thorough peri-operative assessment, careful consideration as to the necessity of the surgical procedure and a frank discussion with the family regarding the risks of anaesthesia and the options available to them.

With limited published data on children with GSD IV undergoing anaesthesia, the anaesthetic recommendations are based upon the authors' perceived best practice.

Dependent on the degree of organ involvement found at the peri-operative assessment, it may be necessary to have two anaesthetists to be present, preferably having experience with children with GSD IV. The child should be fully monitored prior to induction. The period of preoperative fasting should be minimised and peri-operative maintenance fluids commenced as soon as possible to avoid dehydration and hypoglycaemia. Blood sugars should be monitored and appropriate fluid replacement commenced.

The most common, classic form of GSD IV is characterised by progressive cirrhosis. An evaluation by a hepatologist may be warranted and a review of liver function tests should be undertaken along with coagulation studies for procedures [2].

Reports in the medical literature of patients developing progressive accumulation of abnormal glycogen in other organs such as the heart suggest that all children with GSD IV who present for anaesthesia should have a thorough cardiac assessment [2,7–8]. This should include an electrocardiogram (ECG), a recent echocardiogram (ECHO), and where indicated a review by a paediatric cardiologist. This information will help to direct decisions to pursue regional anaesthesia over general anaesthesia and guide an open discussion about the risks of anaesthesia with the child's family.

The rare neuromuscular variant of GSD IV patients characterised by dysfunction of the central and peripheral nervous systems should be reviewed with a careful pre-operative evaluation on status and documentation of neurological deficits. Discussion and counselling should include the risk of deterioration of clinical status, potential need for postoperative respiratory support, and weigh the risks and benefits of regional and general anaesthesia [12].

Particular or additional monitoring

Standard monitoring of vital signs should be performed in all types of anaesthesia including sedation. Monitoring should follow the usual standard and at least comprise ECG, blood pressure, pulse oximetry and continuous measurement of body temperature as well as capnography in ventilated patients.

Possible complications

In the event of cardiac and/or respiratory compromise or arrest, standard national paediatric resuscitation guidelines should apply to children with GSD IV.

Post-operative care

Attentive care of the patient with GSD IV must continue into the post-operative period. Children with significant organ involvement including cardiac must be fully monitored with oxygen saturations, ECG and blood pressure in an intensive care or high-dependency setting for an appropriate period of time after the surgery.

Standard ward post-operative care may be appropriate in some cases but consider 24-hour postoperative supervision in an intensive care unit if there are any concerns.

Disease-related acute problems and effect on anaesthesia and recovery

In the event of cardiac and/or respiratory compromise or arrest, standard national paediatric resuscitation guidelines should apply to children with GSD IV.

Ambulatory anaesthesia

Due to the complexity of GSD IV, ambulatory care is not recommended as part of routine care apart. Inpatient admission and management is suggested as best practice.

Obstetrical anaesthesia

There are no case reports or reviews in the literature of obstetric anaesthesia in patients with a diagnosis of GSD IV. In the past, many children with GSD IV may have not survived to adulthood. Case reports in the literature of adults with myopathy (central and peripheral) suggest the need for consultant obstetric review and careful planning for delivery in conjunction with anaesthesia. The myopathy should be documented including the discussion that was had with the patient with regard to vaginal delivery and the risk of central neuroaxial blockade to the patient [2].

Perioperative assessment should involve routine bloods including full blood count, coagulation studies, blood chemistry including liver function and crossmatch as a baseline and further investigations dependent on clinical examination and findings as in paediatrics. If liver dysfunction is present, it may be pertinent to consider whether spinal/epidural anaesthesia is appropriate. Peri-operatively, the risk of bleeding may be higher if liver dysfunction is present, and this should be planned for and discussions had with hepatologists and haematologists to ensure best care.

References

1. Escobar LF, Wagner S, Tucker M, Wareham J. Neonatal presentation of lethal neuromuscular glycogen storage disease type IV. *J Perinatol* 2012;32:810–813. DOI: 10.1038/jp.2011.178
2. Servidei S, et al. Severe cardiopathy in branching enzyme deficiency. *J Pediatr* 1987; 111):51–56
3. Lossos A, et al. Hereditary branching enzyme dysfunction in adult polyglucosan body disease: a possible metabolic cause in two patients. *Ann Neurol* 1991;30:655–662
4. Akman HO, Karadimas C, Gyftodimou Y, Grigoriadou M, Kokotas H, Konstantinidou A, et al. Prenatal diagnosis of glycogen storage disorder type IV. *Prenat Diagn* 2006;26:951–955
5. Bao Y, et al. Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen-branching enzyme gene. *J Clin Invest* 1996;97:941–48
6. Matern D, et al. Liver transplantation for glycogen storage disease types I, III, and IV. *Eur J Pediatr* 1999;158:S43–S48
7. Selby R, et al. Liver transplantation for type IV glycogen storage disease. *New Eng J Med* 1991;324:39–42
8. Starzl TE, et al. Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. *New Eng J Med* 1993;328:745–749
9. Tang TT, et al. Neonatal hypotonia and cardiomyopathy secondary to type IV glycogenosis. *Acta Neuropathol (Berl)* 1994;87:531–536
10. Yu W, Brundler MA, Wright JR Jr. Polyglucosan Bodies in Placental Extravillous Trophoblast for the Diagnosis of Fatal Perinatal Neuromuscular Type Glycogen Storage Disease Type IV. *Pediatr Dev Pathol* 2018;21:423–427. DOI: 10.1177/1093526617707852
11. Cox PM, et al. Early-onset fetal hydrops and muscle degeneration in siblings due to a novel variant of type IV glycogenosis. *Am J Med Genet* 1999;86:187–193
12. Bruno C, et al. Glycogen branching enzyme deficiency in adult polyglucosan body disease. *Ann Neurol* 1993;33:88–93
13. Brown BI, et al. Branching enzyme activity of cultured amniocytes and chorionic villi: prenatal testing for type IV glycogen storage disease. *Am J Hum Genet* 1989;44:378–381
14. Shen J, et al. Prenatal diagnosis of glycogen storage disease type IV using PCR-based DNA mutation analysis. *Prenat Diagn* 1999;19:837–839
15. Armendi A, Patel V, Mayhew J. Anesthetic management in a child with Glycogen Storage Disease IV. *Pediatr Anesth* 2010;20:471–475.

Date last modified: **June 2019**

This recommendation was prepared by:

Authors

Mae Johnson, Department of Anaesthesia, Great Ormond Street Hospital, London, United Kingdom
Mae.Johnson@gosh.nhs.uk

Grant Stuart, Paediatric Anaesthetic Consultant, Department of Anaesthesia, Great Ormond Street Hospital, London, United Kingdom

Disclosure The authors have no financial or other competing interest to disclose. This recommendation was unfunded.

This recommendation was reviewed by:

Reviewers

Alberto de Armendi, Anaesthesiologist, The Children's Hospital, University of Oklahoma Health Science Center, Oklahoma, OK, USA
Alberto-de-Armendi@ouhsc.edu

Sterling Udom, Anaesthesiologist, The Children's Hospital, University of Oklahoma Health Science Center, Oklahoma, OK, USA
Sterling-Udom@ouhsc.edu

Tino Münster, Anaesthesiologist, Department of anaesthesiology and intensive care medicine, Hospital Barmherzige Brüder, Regensburg, Germany
Tino.Muenster@barmherzige-regensburg.de

Disclosure The reviewers have no financial or other competing interest to disclose.

Please note that this recommendations was not reviewed by an anaesthesiologist and a different disease expert, but by anaesthesiologists only.

Herausgeber



DGAI

Deutsche Gesellschaft
für Anästhesiologie und
Intensivmedizin e.V.
Präsident: Prof. Dr.
R. Rossaint, Aachen



BDA

Berufsverband Deutscher
Anästhesisten e.V.
Präsident: Prof. Dr.
G. Geldner, Ludwigsburg



DAAF

Deutsche Akademie
für Anästhesiologische
Fortbildung e.V.
Präsident: Prof. Dr.
H. Bürkle, Freiburg

Schriftleitung

Präsident/in der Herausgeberverbände
Gesamtschriftleiter/Editor-in-Chief:
Prof. Dr. Dr. Kai Zacharowski, Frankfurt
Stellvertretender Gesamtschriftleiter/
Deputy Editor:
Prof. Dr. T. Volk, Homburg/Saar
CME-Schriftleiter/CME-Editor:
Prof. Dr. W. Zink, Ludwigshafen

Redaktionskomitee/Editorial Board

Prof. Dr. G. Beck, Wiesbaden
Dr. iur. E. Biermann, Nürnberg
Prof. Dr. H. Bürkle, Freiburg
Prof. Dr. B. Ellger, Dortmund
Prof. Dr. K. Engelhard, Mainz
Prof. Dr. M. Fischer, Göttingen
Priv.-Doz. Dr. T. Iber, Baden-Baden
Prof. Dr. U. X. Kaisers, Ulm
Prof. Dr. T. Loop, Freiburg
Prof. Dr. W. Meißner, Jena
Prof. Dr. C. Nau, Lübeck
Dr. M. Rähmer, Mainz
Prof. Dr. A. Schleppers, Nürnberg
Prof. Dr. M. Thiel, Mannheim
Prof. Dr. F. Wappler, Köln
Prof. Dr. M. Weigand, Heidelberg

Redaktion/Editorial Staff

Carolin Sofia Kopp B.A.
Korrespondenzadresse: Roritzerstraße 27 |
90419 Nürnberg | Deutschland
Tel.: 0911 9337812 | Fax: 0911 3938195
E-Mail: anaesth.intensivmed@dgai-ev.de

Verlag & Druckerei

Aktiv Druck & Verlag GmbH

An der Lohwiese 36 |
97500 Ebelsbach | Deutschland
www.aktiv-druck.de



Geschäftsführung

Wolfgang Schröder | Jan Schröder |
Nadja Schwarz
Tel.: 09522 943560 | Fax: 09522 943567
E-Mail: info@aktiv-druck.de

Anzeigen | Vertrieb

Pia Engelhardt
Tel.: 09522 943570 | Fax: 09522 943577
E-Mail: anzeigen@aktiv-druck.de

Verlagsrepräsentanz

Jürgen Distler
Roritzerstraße 27, 90419 Nürnberg
Tel.: 0171 9432534 | Fax: 0911 3938195
E-Mail: jdistler@bda-ev.de

Herstellung | Gestaltung

Pia Engelhardt | Stefanie Triebert
Tel.: 09522 943570 | Fax: 09522 943577
E-Mail: ai@aktiv-druck.de

Titelbild

Gestaltung: Klaus Steigner
Paumgartnerstraße 28 | 90429 Nürnberg
E-Mail: mazyblue@klaus-steigner.de
www.klaus-steigner.de

Erscheinungsweise 2020

Der 61. Jahrgang erscheint jeweils zum
Monatsanfang, Heft 7/8 als Doppelausgabe.

Bezugspreise (inkl. Versandkosten):

• Einzelhefte	30,- €
• Jahresabonnement:	
Europa (ohne Schweiz)	258,- €
(inkl. 7 % MwSt.)	
Schweiz	266,- €
Rest der Welt	241,- €

Mitarbeiter aus Pflege, Labor, Studenten und Auszubildende (bei Vorlage eines entsprechenden Nachweises)

Europa (ohne Schweiz)	94,- €
(inkl. 7 % MwSt.)	
Schweiz	90,- €
Rest der Welt	94,- €

**Für Mitglieder der DGAI und/oder
des BDA ist der Bezug der Zeitschrift
im Mitgliedsbeitrag enthalten.**

Allgemeine Geschäfts- und Liefer- bedingungen

Die allgemeinen Geschäfts- und Liefer-
bedingungen entnehmen Sie bitte dem
Impressum auf www.ai-online.info

Indexed in **Current Contents®/Clinical
Medicine, EMBASE/Excerpta Medica;
Medical Documentation Service;
Research Alert; Sci Search; SUBIS
Current Awareness in Biomedicine;
VINITI: Russian Academy of Science.**

Nachdruck | Urheberrecht

Die veröffentlichten Beiträge sind urhe-
berrechtlich geschützt. Jegliche Art von
Vervielfältigungen – sei es auf mechani-
schem, digitalem oder sonst möglichem
Wege – bleibt vorbehalten. Die Aktiv
Druck & Verlags GmbH ist allein auto-
risiert, Rechte zu vergeben und Sonder-
drucke für gewerbliche Zwecke, gleich
in welcher Sprache, herzustellen. An-
fragen hierzu sind nur an den Verlag zu
richten. Jede im Bereich eines gewerbli-
chen Unternehmens zulässig hergestellte
oder benutzte Kopie dient gewerblichen
Zwecken gem. § 54 (2) UrhG. Die Wie-
dergabe von Gebrauchsnamen, Handels-
namen, Warenbezeichnungen usw. in
dieser Zeitschrift berechtigt auch ohne
besondere Kennzeichnung nicht zu der
Annahme, dass solche Namen im Sinne
der Warenzeichen- und Markenschutz-
Gesetzgebung als frei zu betrachten wä-
ren und daher von jedermann benutzt
werden dürften.

Wichtiger Hinweis

Für Angaben über Dosierungsanwei-
sungen und Applikationsformen kann
vom Verlag und den Herausgebern keine
Gewähr übernommen werden. Derartige
Angaben müssen vom jeweiligen An-
wender im Einzelfall anhand anderer
Literaturstellen auf ihre Richtigkeit über-
prüft werden. Gleiches gilt für berufs-
und verbandspolitische Stellungnahmen
und Empfehlungen.

Die Beiträge aus der A&I finden Sie online unter: www.ai-online.info

CONTACT US

Please do not hesitate to contact us. We will be glad to answer and provide further information to you at any time.

.....
Name

.....
First Name

.....
Department / Hospital

.....
Place

.....
Telephone

.....
E-Mail

.....
Date / Signature

Please contact me for further information

☐

I would like to participate in the project

☐

ADDRESS

German Society of Anaesthesiology and
Intensive Care Medicine
Ursula Homberg
Roritzerstrasse 27 | 90419 Nuremberg | Germany
Tel.: +49-911-9337828 | Fax: +49-911-3938195
Email: uhomberg@orphananesthesia.eu